Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies

NCT04767308 | Unknown Early Phase 1

• 1 other identifier: CT125ACI001
• Study Type: interventional
• Target: 18
• Locations: 0 countries
• Sites: N/A

Brief Summary

Current treatments for relapsed/refractory hematopoietic malignancies such as B-cell lymphomas (BCLs) and peripheral T-cell lymphomas (PTCLs) are far from satisfactory. CD5 is widely expressed in multiple subtypes of BCLs and PTCLs but rarely found in normal tissues except certain types of lymphocytes. Chimeric antigen receptor (CAR) T cells against CD5 offer another potential therapeutic option for patients with relapsed/refractory CD5 positive hematopoietic malignancies. In the current study, the safety and efficacy of a novel CAR T cell therapy, termed CT125A cells, are evaluated in patients with relapsed/refractory CD5+ hematopoietic malignancies. The endogenous CD5 in CT125A cells is knocked out via CRISPR/Cas9 genome editing technology to prevent fratricide during CAR T cells manufacturing.

Conditions

CD5+ Relapsed/Refractory Hematopoietic Malignancies; Chronic Lymphocytic Leukemia (CLL); Mantle Cell Lymphoma (MCL); Diffuse Large B-cell Lymphoma (DLBCL); Follicular Lymphoma (FL); Peripheral T-cell Lymphomas (PTCL)

Keywords

Adoptive T Cell Therapy; Chimeric antigen receptor; CD5 / Lymphocyte antigen T1/Leu-1; CD5+ hematopoietic malignancies

Outcome Measures

Primary Outcomes (2)

• Incidence and types of dose limited toxicities (DLTs) following infusion of CT125A chimeric antigen receptor (CAR) T cells

  Incidence and types of dose limited toxicities (DLTs) after administration of CT125A cells in patients with relapsed/refractory CD5+ hematopoietic malignancies will be recorded at 3 dose levels to investigate the maximum tolerated dose of CT125A. DLT is defined as the following adverse events that occur during the first 28 days after CT125A infusion and are definitely or probably related to CT125A cells: 1) Cytokine release syndrome equal or greater than grade 4 lasting longer than 3 days graded by ASTCT 2019 consensus; 2) Grade 4 immune effector cell-associated neurotoxicity syndrome graded by ASTCT 2019 consensus; 3) Grade 4 hematological toxicity lasting longer than 28 days except for T cell aplasia; 4) Non-hematological toxicity equal or greater than grade 3 lasting longer than 7 days or Grade 4 non-hematological toxicity lasting longer than 3 days.

  28 days after CAR T cell infusion

• Incidence and severity of adverse events (AEs) following infusion of CT125A chimeric antigen receptor (CAR) T cells

  Incidence of adverse events (AEs) after administration of each dose of CT125A cells in patients with relapsed/refractory CD5+ hematopoietic malignancies will be recorded and the severity of AEs will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 except that cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome will be graded according to the consensus by ASTCT in 2019. AE is defined as any untoward medical occurrence in a patient after CAR T cell infusion and which does not necessarily have a causal relationship with this treatment.

  2 years after CAR T cell infusion

Secondary Outcomes (3)

• Overall response rate (ORR) at 4th week and 12th week

  12 weeks after CAR T cell infusion

• Time to first response after CT125A cells infusion

  2 years after CAR T cell infusion

• Time to complete response (CR) after CT125A infusion

  2 years after CAR T cell infusion

Other Outcomes (7)

• Best overall response (BOR) 3 months after CT125A cells infusion

  3 months after CAR T cell infusion

• Duration of response (DOR)

  2 years after CAR T cell infusion

• Progression free survival (PFS)

  2 years after CAR T cell infusion

Study Arms (1)

Arm 1

EXPERIMENTAL

The tolerability and safety of CT125A cells will be assessed according to the "3+3" dose escalation design. There will be three dose levels, 1×10\^6, 2×10\^6, and 3×10\^6, CAR+T cells/kg. For each level, 1-3 subjects will be enrolled. If no dose limited toxicity (DLT) occurs, next level will be assessed for DLT. If DLT occurs in one subject, 3 more subjects will be enrolled in this cohort for the evaluation of DLT. If DLT occurs in ≤ 1/6 subjects, next level will be assessed for DLT. If DLT occurs in ≥ 2 subjects, no more subjects will be enrolled in this cohort and dose escalation will be canceled. For each cohort, following subjects can only receive CT125A infusion at least 14 days after the first subject received CT125A infusion. If DLT occurs in 2 subjects at Dose Level 1, whether to explore a lower dose will be determined by the investigator. After dose escalation phase is completed, the dose for extension phase will be determined based on safety and PK data.

Biological: CT125A cells; Drug: Cyclophosphamide, fludarabine

Interventions

CT125A cells BIOLOGICAL

Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to manufacture CT125A cells, during which cyclophosphamide and fludarabine will be administered for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with CT125A cells by intravenous (IV) infusion. The initial dose of 1×10\^6 CAR+ T cells/kg will be infused on day 0.

Arm 1

Cyclophosphamide, fludarabine DRUG

Subjects will be given IV infusion of cyclophosphamide 500 mg/m2/day and fludarabine 30 mg/m2/day on days -4, -3 and -2

Arm 1

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects with CD5 positive B-cell lymphomas must meet the diagnostic criteria from National Comprehensive Cancer Network (NCCN) guidelines for B-Cell Lymphomas (2020.V1) and have CD5 expression on lymphoma cells (results within 60 days before informed consent signing are acceptable if current clinical condition is not suitable for sampling, and the investigator will judge whether the test results from other hospitals are acceptable and whether they can be enrolled); according to Lugano 2014 criteria, patients with B-cell lymphomas have at least one measurable lesion with the longest diameter ≥ 1.5 cm or bone marrow involvement detected by flow cytometry .
• Including:
• Chronic lymphocytic leukemia/small lymphocytic lymphoma: any BTK inhibitor have been given for at least 6 months and the treatment has failed (SD or PD).
• Mantle cell lymphoma (MCL): patients with MCL must have relapsed/refractory diseases after receiving at least one treatment regimen. Previous treatment must include chemotherapy with anthracyclines or bendamustine, anti-CD20 monoclonal antibody, and any BTK Inhibitor therapy.
• Diffuse large B-cell lymphoma: patients with diffuse large B-cell lymphoma who have failed or relapsed after at least two lines of therapy (a standard chemotherapy and a rescue chemotherapy); and meet one of the following conditions: a. unable to receive autologous hematopoietic stem cell transplantation (autoHSCT); b. refuse to receive autoHSCT; c. relapse after autoHSCT.
• Subjects with CD5 positive peripheral T-cell lymphomas (PTCLs) are diagnosed according to criteria from World Health Organization classification for tumors of the hematopoietic and lymphoid tissues (2016 Edition) and have CD5 expression on lymphoma cells (results within 60 days before informed consent signing are acceptable if current clinical condition is not suitable for sampling, and the investigator will judge whether the test results from other hospitals are acceptable and whether they can be enrolled); according to Lugano 2014 criteria, patients with T-cell lymphomas must have at least one measurable lesion with the longest diameter ≥ 1.5 cm and no bone marrow involvement confirmed by flow cytometry and gene rearrangement (TCR/IGH) tests (and PET-CT results, if any, that must indicate no increased bone marrow metabolism); patients must fail or relapse after at least one line of therapy; including but not limited to the following PTCLs:
• Peripheral T cell lymphoma - not otherwise specified (PTCL-NOS)
• Angioimmunoblastic lymphoma
• ALK negative anaplastic large cell lymphoma
• Extranodal NK/T cell lymphoma
• Enteropathy-associated T-cell lymphoma
• Large granular T lymphocyte leukemia
• Adult T cell leukemia
• Age ≥18 and ≤70 years old, regardless of gender.
• Expected life expectancy ≥12 weeks.

You may not qualify if:

• Subjects who meet any of the following criteria will be excluded:
• History of allergies to any of the ingredients in cell products.
• Patients with acute GVHD judged to be grade II-Ⅳ by Glucksberg criteria or grade B-D by IBMTR index; acute or chronic GVHD patients who need systemic treatment within four weeks before enrollment.
• Injected with live vaccines within 4 weeks before enrollment.
• Severe active infection (except simple urinary tract infection and bacterial pharyngitis), or currently receiving intravenous antibiotic treatment. However, preventive antibiotics, antiviral and antifungal infection treatments are permitted.
• Hepatitis B surface antigen (HBsAg) positive or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA \> 100 IU/mL.
• Hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C virus (HCV) RNA positive.
• Subjects with other acquired and congenital immunodeficiency diseases, including but not limited to human immunodeficiency virus (HIV) antibody positive; subjects with cytomegalovirus (CMV) DNA \> 400 copy/mL; subjects with syphilis test positive.
• Cardiac insufficiency of grade III or IV according to the New York Heart Association (NYHA) cardiac function classification criteria.
• History of other primary cancers, except for the following conditions:
• )Non-melanoma skin cancer with complete resection, such as basal cell carcinoma; 2)Cured carcinoma in situ such as cervical cancer, bladder cancer or breast cancer; 3)No recurrence of other primary cancers has been found for more than 5 years after treatment.
• History of solid organ transplantation.
• Subjects with previous autoimmune diseases (mainly abnormality of cellular immunity), immunodeficiency or subjects requiring immunosuppressive therapy.
• Received other interventional clinical trial treatment within 3 months before signing ICF.
• Pregnant or lactating women.

Sponsors & Collaborators

• Huazhong University of Science and Technology: lead
• Shanghai IASO Biotechnology Co., Ltd: collaborator

Related Publications (2)

• Cheng J, Zhu L, Wu J, Zeng Y, Mao X, Ding S, Wang J, Xiao Y, Zhou X, Mu W, Zhu X. Efficacy and safety of autologous CD5-KO anti-CD5 CAR-T cells in relapsed/refractory CD5+ hematological malignancies. Cell Rep Med. 2026 Feb 2:102584. doi: 10.1016/j.xcrm.2026.102584. Online ahead of print.

  PMID: 41633358 DERIVED

• Mu W, Zhang M, Hu G, Han Y, Mao X, Chen C, Shen K, Dai Z, Zhu X, Zhou X, Huang L, Ao Q, Xiao M. Case report: Differential diagnosis of highly amplified anti-CD5 CAR T cells and relapsed lymphoma cells in a patient with refractory ALK positive anaplastic large cell lymphoma. Front Immunol. 2023 Dec 8;14:1280007. doi: 10.3389/fimmu.2023.1280007. eCollection 2023.

  PMID: 38143760 DERIVED

MeSH Terms

Conditions

Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, T-Cell, Peripheral

Interventions

CF regimen

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Leukemia, B-Cell; Leukemia, Lymphoid; Leukemia; Neoplasms by Histologic Type; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell

Study Officials

• Jianfeng Zhou, PhD, MD

  Huazhong University of Science and Technology

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jianfeng Zhou, PhD, MD

CONTACT

86-27-83662680; jfzhou@tjh.tjmu.edu.cn

Jin Huang, PhD, MD

CONTACT

86-27-83662680; hj20130318@163.com

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: February 9, 2021
• First Posted: February 23, 2021
• Study Start: March 1, 2021
• Primary Completion: September 1, 2023
• Study Completion: December 1, 2023
• Last Updated: February 23, 2021

Record last verified: 2021-02

Data Sharing

• IPD Sharing: Will share